

DATE OF AGM AND CLOSING DATE FOR DIRECTOR NOMINATIONS

Perth, Australia; 17 September 2024 – Argenica Therapeutics Limited (Argenica or Company) (ASX: AGN) advises, in accordance with ASX Listing Rule 3.13.1, that its Annual General Meeting (AGM) will be held on Tuesday, 12 November 2024.

The location of the meeting and details of all resolutions to be considered at the AGM will be contained in a Notice of AGM and Explanatory Memorandum which will be dispatched to shareholders prior to the meeting.

In accordance with the Company's constitution, any person wishing to be considered for election as a director of the Company must submit a nomination which must be received at the Company's registered office no later than Tuesday, 24 September 2024.

This announcement has been approved for release by the Company Secretary

For more information please contact: info@argenica.com.au

ABOUT ARGENICA

Argenica (ASX: AGN) is developing novel therapeutics to reduce brain tissue death after stroke and other types of brain injury and neurodegenerative diseases to improve patient outcomes. Our lead neuroprotective peptide candidate, ARG-007, has been successfully demonstrated to improve outcomes in pre-clinical stroke models, traumatic brain injury (TBI) and hypoxic ischaemic encephalopathy (HIE). The Company has completed a Phase 1 clinical trial in healthy human volunteers to assess the safety and tolerability of a single dose of ARG-007. Argenica has now initiated a Phase 2 clinical trial in acute ischaemic stroke patients, as well as continuing to generate preclinical data in other neurological conditions.